Outcomes of bispecific antibody therapy after CAR T-cell failure in relapsed/refractory large B-cell lymphoma

Outcomes of bispecific antibody therapy after CAR T-cell failure in relapsed/refractory large B-cell lymphoma

Abstract: Patients with large B-cell lymphoma (LBCL) who experience relapsed disease after CD19-directed chimeric antigen receptor (CAR) T-cell (CAR-T) therapy have a poor prognosis. Bispecific antibodies (BsAbs) induce complete remissions in ∼35% of these cases. Hypothesizing overlapping LBCL-intri...

Full description

Saved in:
Bibliographic Details
Main Authors: Evgenii Shumilov, Julia Katharina Scholz, Maximilian Seib, Paolo Mazzeo, Rebecca Wurm-Kuczera, Vladan Vucinic, Udo Holtick, Hristo Boyadzhiev, Thomas Melchardt, Alexander Hölscher, Christian Schultze-Florey, Atef Abdelhafez, Giuliano Filippini Velazquez, Anna Ossami Saidy, Vadim Lesan, Ulf Schnetzke, Andrea Kerkhoff, Ulrike Bacher, Susanne Ghandili, Enver Aydilek, Niklas Gebauer, Thomas Weber, Gerald Wulf, Bertram Glass, Lorenz Thurner, Florian H. Heidel, Christoph Schmid, Andreas Viardot, Mathias Hänel, Sascha Dietrich, Thomas Pabst, Francis Ayuk, Bastian von Tresckow, Björn Chapuy, Christiane Pott, Fabian Müller, Georg Lenz
Format: Article
Language:English
Published: Elsevier 2025-08-01
Series:Blood Advances
Online Access:http://www.sciencedirect.com/science/article/pii/S2473952925002289
Tags: Add Tag
No Tags, Be the first to tag this record!
Be the first to leave a comment!
You must be logged in first

Similar Items